Janux Therapeutics, Inc. Interest Expense
| Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|
| Interest Expense | $233.0K | $206.0K | $0.0 | $4,032.0K | $0.0 | $0.0 |
Janux Therapeutics, Inc. (JANX) Interest Expense comparison analysis
General
LTM Interest Expense
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
JANX key stats
| Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 3.6 0.0% | 8.6 136.8% | 8.1 (6.1%) | 10.6 31.0% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.1 | 0.8 | 2.0 | 0.0 |
% margin | (0.0) 0.0% | (0.0) 0.0% | 3.5 96.9% | 7.8 90.2% | 6.1 75.8% | 10.6 100.0% |
| Operating Expenses | 3.8 | 4.8 | 36.6 | 75.7 | 81.1 | 109.4 |
| Research & Development Expenses (R&D) | 3.0 | 3.0 | 26.2 | 53.4 | 54.9 | 68.4 |
| Selling, General & Administrative Expenses (SG&A) | 0.8 | 1.8 | 10.3 | 22.3 | 26.1 | 41.0 |
% margin | (3.8) 0.0% | (4.8) 0.0% | (32.9) (905.4%) | (67.1) (779.0%) | (73.0) (902.9%) | (98.8) (933.6%) |
| Interest Income | 0.2 | 0.2 | 0.3 | 4.0 | 14.7 | 29.9 |
| Interest Expense | 0.2 | 0.2 | 0.0 | 4.0 | 0.0 | 0.0 |
| Pre-tax Income | (4.0) | (6.8) | (32.7) | (63.1) | (58.3) | (69.0) |
% effective tax rate | 0.2 (5.8%) | (1.5) 22.5% | (0.1) 0.3% | (8.9) 14.1% | 0.0 0.0% | 0.0 0.0% |
% margin | (4.2) 0.0% | (5.3) 0.0% | (32.6) (895.2%) | (54.2) (628.8%) | (58.3) (721.2%) | (69.0) (651.6%) |
| EPS | (0.10) | (0.13) | (0.79) | (1.31) | (1.32) | (1.28) |
| Diluted EPS | (0.10) | (0.13) | (0.79) | (1.31) | (1.32) | (1.28) |
% margin | (3.8) 0.0% | (4.8) 0.0% | (32.8) (902.3%) | (66.3) (769.3%) | (71.0) (878.7%) | (98.8) (933.6%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Janux Therapeutics, Inc.'s Interest Expense?
As of today, Janux Therapeutics, Inc.'s last 12-month Interest Expense is $0.0, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Janux Therapeutics, Inc.'s Interest Expense growth rate?
Over the last year, Janux Therapeutics, Inc.'s Interest Expense growth was (100.0%). The average annual Interest Expense growth rates for Janux Therapeutics, Inc. have been N/A over the past three years, (100.0%) over the past five years.
3) Is Janux Therapeutics, Inc.'s Interest Expense growth rate Good?
Over the last year, Janux Therapeutics, Inc.'s Interest Expense growth was (100.0%), which is lower than industry growth of (0.7%). It indicates that Janux Therapeutics, Inc.'s Interest Expense growth is Good.